You have access to thisebookThis definitive volume will provide the reader with up to date information and the most recent science of the fast-evolving area of nanobiotherapeutic-based blood substitutes. Long studied, there are recent updates that make their use in patients more promising, and with one product approved for human use, many more in the pipeline. These include 2nd generations and even third generation ones, the later with enhancement of red blood cell functions. In addition, there are carefully written and referenced updates on the recent history and products in the field, complete with pathophysiologic and pharmacologic studies to validate and verify the efficacy and safety of many of these new products.
Sample Chapter(s)
Chapter 1.1: Unlimited Potential of Nanobiotechnology-based Blood Substitutes, Artificial Cells and Nanobiotherapeutics
Contents:
- Introduction:
- Unlimited Potential of Nanobiotechnology-based Blood Substitutes, Artificial Cells and Nanobiotherapeutics (Thomas Ming Swi Chang)
- General:
- Guiding Principles for Designing Research on HBOCs (Zhou Wentao, Zhang Honghui, Chen Gang, Li Shen, Li Yaojin, Hao Shasha, Li Fengjuan, Wang Hong, Liu Jiaxin and Yang Chengmin)
- The Clinical Impact of Red Blood Cell Storage: What Have the RCTs Told Us? (CP Stowell)
- Rational, Evidence-based Transfusion: A Physiologist's Perspective (George P Biro)
- Hemoglobin-based Oxygen Carriers, Volume Expansion, Fluid Management and Anemia (TN Estep)
- Development and Future of Chinese Transfusion Medicine and Blood Substitutes (Jiaxin Liu and Chengmin Yang)
- Hemoglobin-Based Oxygen Carriers:
- Nanobiotechnology-based Oxygen Carriers (Thomas Ming Swi Chang)
- Hemoglobin-glutamer 250 (Bovine) [HBOC-201, Hemopure®] Clinical Use in South Africa and Comprehensive Review of Cardiac Outcomes and Risk/Benefit in Peer-Reviewed, Indexed Studies in Humans and Animal Models (Jonathan S Jahr, Kelly Tseng, Adam P Brown and Gregory P Dubé)
- Immune Safety Evaluation of Polymerized Porcine Hemoglobin (pPolyHb) — Potential Red Blood Cell Substitutes (Hongli Zhu, Kunping Yan, Xiaodong Dang, He Huang, Erfang Chen Bang Chen, Chao Luo, Thomas Ming Swi Chang, Penggao Dai and Chao Chen)
- Hemoglobin-based Oxygen Carriers and Inhaled Nitric Oxide (Binglan Yu and Warren M Zapol)
- Hemoglobin-based Oxygen Carriers and Myocardial Infarction: Assessment of Potential Mechanisms (TN Estep)
- Insights into the Possible Mechanisms of Hemoglobin-based Oxygen Carrier-Mediated Bradycardia and Adverse Cardiac Effects Observed in Clinical Trials (Hae Won Kim)
- Modulation of Oxygen Affinity in Hemoglobin-based Oxygen Carriers (Esra'a Ali Mohammad Alomari, Luca Ronda, Stefano Bettati, Andrea Mozzarelli and Stefano Bruno)
- Cysteine Mutations in Recombinant Fetal Hemoglobin Influence Oxidative Side-Reactions (Karin Kettisen and Leif Bülow)
- Analysis of Dimeric αβ Subunit Exchange between Bis-Pegylated and Native Hemoglobins (Takashi Matsuhira, Keizo Yamamoto and Hiromi Sakai)
- Ring-opening Polymerization of Hemoglobin Based on Supramolecular Chemistry (Takashi Matsuhira, Keizo Yamamoto and Hiromi Sakai)
- The Application of Hemoglobin-based Oxygen Carriers in Liver Cancer Treatment in Rodent Models (Xiaobing Liu, Chang Xian Li, Xiang Qi, Bing Lou Wong and Kwan Man)
- Hemoglobin-Based Oxygen Carriers with Antioxidant Activities:
- Unraveling of Hemoglobin Oxidative Toxicity: Thirty Years of Investigation (Abdu I Alayash)
- A Nanobiotechnologic Therapeutic that Transports Oxygen and Removes Oxygen Radicals (Thomas Ming Swi Chang)
- Effects of Crosslinked Polyhemoglobin-Superoxide Dismutase-Catalase on Blood-Brain Barrier and Brain Edema in a Hemorrhagic Shock Transient Global Ischemia Rat Model (D Douglas Powanda and Thomas MS Chang)
- Strategies to Decrease the Oxidative Toxicity of Hemoglobin-Based Oxygen Carriers (Ying Wang, Quan Wang and Lian Zhao)
- Enhancing the Stability of Lumbricus Terrestris Erythrocruorin (LtEc) for Use as a Blood Substitute (Brandon Timm and Jacob Elmer)
- Dual Antioxidant and Pro-Oxidation Effects of Ascorbic Acid on Bovine Hemoglobin (Gang Chen and Thomas Ming Swi Chang)
- Hemoglobin-Based Oxygen Carriers with Enhancement in Both Antioxidant Functions and Carbon Dioxide Transport:
- Soluble Nanobiotherapeutics with Enhancements of All Three Major Red Blood Cell Functions (Thomas Ming Swi Chang)
- A Novel Nanobiotherapeutical Poly-[Hemoglobin-Superoxide Dismutase-Catalase-Carbonic Anhydrase] with No Cardiac Toxicity for the Resuscitation of a 90-minute Sustained Severe Hemorrhagic Shock Rat Model with Two-Third Blood Volume Loss (Yuzhu Bian and Thomas Ming Swi Chang)
- Long Term Safety and Immunological Effects of a Nanobiotherapeutic, Bovine Poly-[Hemoglobin-Catalase-Superoxide Dismutase-Carbonic Anhydrase], After Four Weekly 5% Blood Volume Toploading Followed by a Challenge of 30% Exchange Transfusion (Chen Guo and Thomas Ming Swi Chang)
- Extraction of Superoxide Dismutase, Catalase and Carbonic Anhydrase from Stroma-Free Red Blood Cell Hemolysate for the Preparation of the Nanobiotechnological Complex of PolyHemoglobin-Superoxide Dismutase-Catalase-Carbonic Anhydrase (C Guo, M Gynn and TMS Chang)
- Temperature Stability of Poly-[Hemoglobin-Superoxide Dismutase-Catalase-Carbonic Anhydrase] in the Form of a Solution or in the Lyophilized Form During Storage at -80°C, 4°C, 25°C and 37°C or Pasteurization at 70°C (YZ Bian, C Guo and TMS Chang)
- Biodegradable and Lipid Membrane Nanoencapsulated Nano-Artificial Cells:
- Nanotechnology-Based Complete Artificial Red Blood Cells (Thomas Ming Swi Chang)
- Analysis of Polyethylene-Glycol-Polylactide Nano-Dimension Artificial Red Blood Cells in Maintaining Systemic Hemoglobin Levels and Prevention of Methemoglobin Formation (Thomas MS Chang, Douglas Powanda and WP Yu)
- Effects of PEG-PLA-Nano Artificial Cells Containing Hemoglobin on Kidney Function and Renal Histology in Rats (Zun Chang Liu and Thomas MS Chang)
- Long Term Effects on the Histology and Function of Livers And Spleens in Rats after 33% Toploading of PEG-PLA Nano-Artificial Red Blood Cells (Zun Chang Liu and Thomas MS Chang)
- Polylactide-Polyethylene Membrane Nanoencapsulated Polyhemoglobin-Superoxide Dismutase-Catalase-Carbonic Anhydrase. Nano-Artificial Red Blood Cells that Act as O₂ and CO₂ Carriers with Enhanced Antioxidant Activity (Wei G, Yuzhu Bian and Thomas MS Chang)
- Pre-hospital Resuscitation Strategy Using Hemoglobin Vesicles for Trauma Hemorrhagic Shock with Coagulopathy (Manabu Kinoshita and Kohsuke Hagisawa)
- Translational Research of Hemoglobin Vesicles (Artificial Red Cells) for a Transfusion Alternative and O₂/CO Therapeutics (Hiromi Sakai, Hiroshi Azuma, Hirohisa Horinouchi and Koichi Kobayashi)
- Hemoglobin Vesicles as a Transfusion Alternative for Perioperative Hemorrhage in Thoracic Surgery (Mitsutomo Kohno, Ryo Hashimoto, Hiroto Onozawa, Kana Oiwa, Hirohisa Horinouchi, Hiromi Sakai, Koichi Kobayashi and Masayuki Iwazaki)
- Prevention of Methemoglobin Formation in Artificial Red Cells (Hemoglobin Vesicles) (Hiromi Sakai and Magohei Yamada)
- Carbon Monoxide-Bound Hemoglobin-Vesicles: Current Facts and Potential Medical Applications (Kazuaki Taguchi, Kazuaki Matsumoto, Hiromi Sakai, Toru Maruyama and Masaki Otagiri)
- Influence of Hemoglobin Vesicles on Immune Function (Hiroshi Azuma, Mitsuhiro Fujihara and Hiromi Sakai)
- Membrane Fluidity of Artificial Red Cells Encapsulating a Concentrated Hemoglobin Solution Possessing a High Colloid Osmotic Pressure (Tomoko Kure and Hiromi Sakai)
- Tissue and Organ Preservation:
- Development of a New HBOC for Liver Allograft Preservation in Combination with Machine Perfusion — Clearing the Wait List (Kim D Vandegriff, Ashok Malavalli and William R Light)
- OxyVita® Hb: A Step Forward in Delivering Oxygen Carrying Capacity for Therapeutic Applications (Hanna Wollocko, John Harrington, Jonathan Jahr, Kenneth Steier and Jacek Wollocko)
- Functionality of Albumin-Derived Perfluorocarbon-Based Artificial Oxygen Carriers in the Langendorff Heart (Katja B Ferenz and Michael Kirsch)
- Nanobiotherapeutics as Preservation Fluids for Organs and Cells (Thomas Ming Swi Chang, Wenhua Jiang, Felice D'Agnillo and S Razack)
- Platelet:
- Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodilution Setting (Naomi SW Wong and Thomas MS Chang)
- Megakaryocytes and Platelets from Novel Human Adipose Tissue-Derived Mesenchymal Stem Cells: Development of Cell-Based Regenerative Medicine (Yukako Ono-Uruga, Keiichi Tozawa, Yasuo Ikeda and Yumiko Matsubara)
Readership: Highly interdisciplinary area of interest to: (1) Researchers in blood substitutes, oxygen carriers, carbon dioxide transport. antioxidants, nanobiotechnology, Nanomedicine; (2) Clinicians from Cardiology, Critical Care, Anesthesiology, Surgery, Immunology, Hematology, Transfusion Pediatrics, Trauma, Blood Bankers, Emergency Medicine, Toxicology, Nurses; (3) Administrators and decision makers especially those in Hospital, Government health department, University, Heads of Biomedical departments, Blood Bank.
You have access to thisebookThomas Ming Swi Chang, OC, MD, CM, PhD, FRCPC, FRS[C], Director, Artificial Cells & Organs Research Centre, Professor Emeritus of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Director, " Chang Artificial Cell Translation Research Institute" Faculty of Medicine, Shenzhen University, China; Director, "Academician TMS Chang Research station" Shantou University Medical School, China; Honorary Professors at Peking Union Medical College; Blood Transfusion Institute of the Chinese Academy Medical Sciences and Nankai University; Honorary President, International Society of Artificial Cells, Blood Substitutes & Biotechnology. Editor in Chief, Artificial Cells, Nanomedicine & Biotechnology, an international Journal, Editor in Chief, Regenerative Medicine, Artificial Cells & Nanomedicine, Book Series.
He invented the first artificial red blood cell during his BSc at McGill in 1957. There was no initial interest. He persisted while studying for his MD then PhD (Chang Science 1964, Nature 1971). By breaking "out of the box" of reproducing biological cells, he prepares artificial cells with (1) DIMENSIONS: from macro, micro, nano to soluble nanobiotechnological complexes. (2) CONTENTS; biological cell contents, cells, stem cells, vaccines, magnetic material, adsorbents, (3) MEMBRANES: biological and polymeric with variations in permeability, biodegradability, biocompatibility, targeting abilities etc. His 2019 review https://www.tandfonline.com/doi/full/10.1080/21691401.2019.1577885 shows that ARTIFICIAL CELL has evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent hemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology.
Jonathan S Jahr, MD, DABA, FASA, is Professor Emeritus of Anesthesiology and Perioperative Medicine at UCLA. He has distinguished himself by authoring or co-authoring over 200 publications, co-editing a textbook, and serving on multiple editorial boards of major journals and as a reviewer for the NIH and FDA. His leadership in oxygen therapeutics, from managing and publishing major clinical trials, to understanding the impact of hemoglobin based oxygen carriers on coagulation, have created value for the entire scientific community, and helped foster future products to be developed and tested. As lead investigator in the Hemopure trial in elective orthopedic patients, he presented the largest non-trauma database of subjects receiving an HBOC, and combined with the studies of Hemopure, PolyHeme, and Hemosol, allowed for post-marketing study of Hemopure in South Africa. His animal studies with Oxyglobin in hemodynamics, oxygen delivery, intravital microscopy, laboratory interference, coagulation added to the knowledge base for this FDA and EU approved veterinary product for canine anemia. Additionally, his contributions to major acute pain and other anesthetic medications have bettered patient's care and lives.
Hiromi Sakai received PhD (DEng) in polymer chemistry in 1994 from Waseda Univ., Tokyo, with a thesis entitled "Hemoglobin-vesicles (HbV) as a molecular assembly" (Supervisor, late Prof. E Tsuchida), and since then he has continuously studied the production, safety and efficacy evaluations of HbV. In 1996–1998 he studied at Dept. Bioengineering, UC San Diego (Supervisor, Prof. M Intaglietta) and evaluated the microvascular responses to HbV injection. After coming back to Tokyo, he studied improvement of the stabilization and biocompatibility of HbV and evaluated its safety and efficacy by animal experiments. In 2006 he received PhD (DMedSci) from Keio Univ. School of Medicine (Supervisor, Prof. K Kobayashi). Dr Sakai was a Lecturer and an Associate Professor at Research Institute for Sci.&Eng. Waseda Univ. in 1998–2009, and PI at Waseda Bioscience Research Institute in Singapore in 2009–2013. From 2013 he has been the Professor of Chemistry, Nara Medical University, Kashihara, Japan. He is the chief investigator of the artificial red cells project, aiming at clinical applications, which has been supported by Ministry of Health Labour and Welfare, Japan (MHLW) and the Japan Agency for Medical Research and Development (AMED). From 2019 he is the fourth president of the Society of blood Substitutes, Japan (SBSJ).